News | April 30, 2021
Indian vaccine players to garner Rs. 70,599 Cr in 2021
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
These media reports are based on incorrect facts and are without any basis.
The country has constantly worked with the spirit of public-private partnership
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
Subscribe To Our Newsletter & Stay Updated
